Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03075527 · MORE INFO

Limitations, agreements, and source contact

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
point Of Contact
email
mark_awad@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
6176323468
title
Mark Awad, MD, PhD
Complete source fields
certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
point Of Contact
email
mark_awad@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
6176323468
title
Mark Awad, MD, PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice